Ypsomed
Ypsomed is a Swiss-listed medical device company that designs and manufactures self-injection drug delivery systems—pen injectors, prefilled autoinjectors and wearable patch injectors—sold exclusively B2B to pharmaceutical and biotech companies for use with GLP-1, insulin and biologic therapies.
- Company typePublic
- Founded1984
- HeadquartersBurgdorf, Switzerland
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ypsomed does
Ypsomed is a Switzerland-headquartered, publicly-listed medical device company (SIX: YPSN) that develops and manufactures self-injection drug delivery systems—including pen injectors, two-step prefilled autoinjectors (YpsoMate in 1 mL, 2.25 mL and 5.5 mL variants), the YpsoLoop circular autoinjector, and the 10 mL YpsoDose patch/wearable injector—plus digital add-ons such as the FDA-cleared SmartPilot connectivity module. The company serves pharmaceutical and biotech customers exclusively on a B2B basis, with products integrated into GLP-1 obesity/diabetes, insulin, biologic and biosimilar therapies; named customers include Novo Nordisk, Sanofi (over 1 billion SoloSTAR pen components produced), Abbott, Dexcom, Insulet, BD, SCHOTT Pharma, Stevanato Group and CamDiab. Revenue is generated through hardware sales of injection devices, project/development fees (CHF 85.7 million from a record 44 new customer projects in FY2025/26), and a contract-manufacturing stream (e.g., SoloSTAR for Sanofi) that is being deliberately phased out and moved to the Others segment from FY2026/27 as Ypsomed completes its pivot to pure-play self-injection.
Following the July 2025 sale of mylife Diabetes Care AG to TecMed AG for up to CHF 420 million including earn-out, Ypsomed operates exclusively in injectable drug delivery, with FY2025/26 group revenue of CHF 731.0 million, Delivery Systems revenue of CHF 601.5 million (+20% YoY), Delivery Systems EBIT of CHF 195.5 million (32.5% margin), group EBIT of CHF 246.1 million, ROCE of 20% and net debt/EBITDA of 0.8x. Manufacturing is anchored in Burgdorf and Solothurn (Switzerland) and Schwerin (Germany), with a new Changzhou facility in China (up to 100 million units/year) and a CHF 200 million Holly Springs, North Carolina plant under development for US supply from end of 2027; medium-term targets are CHF 0.9–1.1 billion revenue and CHF 280–340 million EBIT (≥30% margin) by 2029/30, supported by a CHF 150 million completed share buyback and CHF 295.6 million FY2025/26 capex.
Ypsomed firmographics
Firmographics- Name
- Ypsomed
- Legal name
- Ypsomed AG
- Website
- https://ypsomed.com
- Company type
- Public
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Ypsomed is a Swiss-listed medical device company that designs and manufactures self-injection drug delivery systems—pen injectors, prefilled autoinjectors and wearable patch injectors—sold exclusively B2B to pharmaceutical and biotech companies for use with GLP-1, insulin and biologic therapies.
- Ownership category
- akta.pro rank
Ypsomed industry classification
Industry- Product category
- Self-injection drug delivery devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Auto-Injectors (Disposable & Reusable) (HLAHAIAB)
- akta.pro secondary industries
- Wearable Injectors & On-Body Delivery Systems (HLAHAIAE), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Ypsomed is headquartered
LocationHeadquarters
- HQ city
- Burgdorf
- HQ country
- Switzerland
- HQ region
- Europe
Offices6 records
Markets served
Ypsomed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Delivery Systems Product Sales: Revenue from sale of pen injectors, autoinjectors, and wearable injectors to pharmaceutical and biotech customers. Growth driven by GLP-1 medications and biologics market expansion. FY2025/26 Delivery Systems revenue of CHF 601.5 million representing 20% year-on-year growth.
- Project Business / Development Fees: Revenue from new customer project development and capacity reservation fees from pharmaceutical customers. Record 44 new customer projects secured in FY2025/26 with project business revenue of CHF 85.7 million.
- Contract Manufacturing: Manufacturing services for pharmaceutical companies including production of pen components (e.g., SoloSTAR for Sanofi). Being phased out and reported in segment Others for FY2026/27.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels10 records
Ypsomed product offering
Product offeringCore offering
Ypsomed designs, develops, and manufactures self-injection drug delivery systems — pen injectors, prefilled autoinjectors, and wearable patch injectors — together with digital connectivity add-ons, and sells them exclusively in large batches to pharmaceutical and biotechnology companies for use with their drug products. The company leverages a proprietary modular platform architecture to customize delivery devices rapidly and supports customers with regulatory, clinical trial, and manufacturing services across global facilities in Switzerland, Germany, China, and a forthcoming U.S. site.
Product overview
Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. The product portfolio includes pen injectors (YpsoPen, ServoPen, UnoPen, YpsoFlow, YpsoDot, FixPen, LyoTwist), autoinjectors (YpsoMate in 1 mL, 2.25 mL, and 5.5 mL variants, YpsoLoop), wearable injectors (YpsoDose), and digital health solutions (SmartPilot connectivity add-on, CliniPilot, therapy management, connected devices). The company also operates an Innovation Hub developing sustainable solutions including reusable mechanical autoinjectors and circularity initiatives. Ypsomed serves pharmaceutical and biotech companies with contract manufacturing and development services, including the Clear-to-Clinic program for clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- UnoPen: Prefilled variable dose pen injector for GLP-1 and peptide therapies
- ServoPen
- YpsoPen
- YpsoFlow
- FixPen
- LyoTwist
- VarioJect
- YpsoLoop
- YpsoMate
- YpsoMate 2.25/Pro
- YpsoMate 5.5
- SmartPilot
- CliniPilot
- YpsoDose
- YpsoDot
- Clear to Clinic
- Reusable Mechanical Autoinjector
Products and services
- YpsoPen Reusable pen injector for GLP-1, insulin and other peptide therapies, featuring variable dose functionality for pharmaceutical and biotech customers.
- ServoPen Reusable pen injector designed for GLP-1, insulin and other peptide therapies, supplied to pharmaceutical customers.
- UnoPen Prefilled variable dose pen injector for GLP-1 and peptide therapies, offering single-use convenience for pharmaceutical customers.
- YpsoFlow Prefilled, spring-powered pen injector designed for peptide therapies, launched as a new platform in 2025 for pharmaceutical and biotech customers.
- YpsoDot Next-generation pull-push pen injector launched in 2025 for pharmaceutical and biotech customers.
- FixPen Prefilled fixed-dose pen injector for peptide therapies, supplied to pharmaceutical customers.
- LyoTwist Reconstitution auto-injector for lyophilized drugs, enabling self-administration of drugs requiring reconstitution by patients.
- YpsoMate (1 mL) 1 mL two-step prefilled autoinjector for GLP-1 and other medications, featuring push-on-skin activation; widely used by pharmaceutical customers including Novo Nordisk (long-term supply contract).
- YpsoMate 2.25 / Pro 2.25 mL two-step prefilled autoinjector for biologics and other higher-volume medications, supplied to pharmaceutical customers.
- YpsoMate 5.5 5.5 mL large-volume prefilled autoinjector for biologics, designed for high-dose subcutaneous injections in oncology, autoimmune, rare diseases, and metabolic disorders.
- YpsoLoop First autoinjector platform designed for circularity, with 1 mL and 2 mL versions enabling automated disassembly and efficient recycling while offering prefilled two-step autoinjector convenience. Awarded the CPHI Innovation Award.
- VarioJect Versatile variable dose autoinjector for syringes and cartridges, supplied to pharmaceutical customers.
- YpsoDose 10 mL prefilled and pre-assembled patch injector for biologics, enabling subcutaneous delivery of larger volumes for pharmaceutical and biotech customers.
- SmartPilot for YpsoMate FDA-cleared digital connectivity add-on that transforms the YpsoMate autoinjector into a connected system that automatically captures and transmits injection data for therapy monitoring and adherence.
- Clear-to-Clinic Program enabling clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors in clinical trials to accelerate, simplify and de-risk pharmaceutical development programs.
Quantifiable outcome
- 33.6% growth in commercial autoinjector sales
- +4 more outcomes
Companies that use Ypsomed
Customer profileNamed customers6 records
Segments1 record
Ideal customer profiles1 record
Ypsomed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature6 records
Ypsomed partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered strategic and core.
- Stevanato GroupstrategicCollaboration on integration of EZ-fill prefilled syringes into YpsoMate platform and expanding capacity for high-viscosity formulations for large-volume biologic delivery.
- Digital Medicine Society (DiMe)strategicFounding partner in DiMe's Optimizing Direct-to-Patient (DTP) Strategies initiative to establish operational, regulatory, and evidence-based foundations for scaling direct-to-patient healthcare models responsibly.
- AbbottcoreIntegration of Abbott's FreeStyle Libre CGM sensors with Ypsomed's mylife Loop automated insulin delivery system. FreeStyle Libre 2 and 3 integrated with Tandem's t:slim X2 pump and Ypsomed's mylife Loop for automated insulin dosing. Partnership with CamDiab also integrated in Germany.
- BD (Becton, Dickinson and Company)corePartnership to develop large-volume glass syringes for high-dose biologics. BD's Neopak XtraFlow glass prefillable syringes integrated with Ypsomed's YpsoMate 5.5 autoinjector platform for high-viscosity biologic drug delivery. Expanded in 2026 with 5.5mL version development featuring shorter 8mm needle and thinner wall cannulas.
- Sidekick HealthstrategicPartnership combining Ypsomed's injection systems with Sidekick's digital health, behavioral economics and gamification expertise to offer motivating and personalized patient experience for chronic disease management.
- S3 Connected HealthstrategicPartnership to expand digital health offering for pharmaceutical companies to support patients with acute and chronic diseases through integrated device and digital health solutions.
- CamDiab LtdcoreCooperation with CamDiab, developer of CamAPS FX algorithm, to launch automated insulin dosing system for mylife YpsoPump users. Self-learning adaptive algorithm running on smartphone for better glucose control. Solution available for Android and iOS.
- DexcomcorePartnership to establish hybrid closed-loop system for diabetes therapy. Glucose data from Dexcom CGM sensors integrated directly into mylife app for automated insulin delivery.
- Insulet CorporationstrategicExclusive distribution of OmniPod patch pump from Insulet in Europe, China and Australia. The mylife OmniPod is glued directly to the skin at injection site. Built customer base of 70,000 patients by 2018.
Scale indicators24 records
Recent moves11 records
Expansion highlights5 records
Ypsomed competitors and assessment
Company assessmentDirect peers
- BD (Becton, Dickinson and Company) – Pharmaceutical Systems: BD Pharmaceutical Systems is the global leader in prefillable syringe systems and is Ypsomed's direct development partner (Neopak XtraFlow 5.5mL for YpsoMate 5.5) and direct competitor in drug-delivery combination products serving pharma and biotech customers.
- West Pharmaceutical Services: West Pharmaceutical Services is a leading provider of drug containment and delivery components including elastomeric stoppers, seals, and self-injection device platforms (e.g., SmartDose, Confidose), directly competing with Ypsomed's autoinjector and wearable injector portfolio.
- SHL Medical: SHL Medical is one of Ypsomed's closest direct competitors in autoinjector and pen-injector platforms, supplying major pharma companies with devices like Molly, DAI, and reusable pen systems globally.
- Stevanato Group: Stevanato Group is an Italian drug containment and delivery player offering glass syringes (EZ-fill), vial, and device platforms; a recent Ypsomed collaboration expands EZ-fill integration with YpsoMate for high-viscosity biologics, positioning Stevanato as both partner and adjacent competitor.
- Gerresheimer: Gerresheimer is a top-tier global supplier of pharmaceutical glass and plastic primary packaging plus drug-delivery devices (incl. syringe systems and autoinjectors), competing with Ypsomed for prefilled syringe and combination-product business.
- SCHOTT Pharma: SCHOTT Pharma supplies pharmaceutical glass including syringQ BioPure prefillable syringes; the 5.5mL syringe integrated with YpsoMate 5.5 positions SCHOTT as a key component partner and competitor for prefilled syringe contents feeding Ypsomed-class devices.
- Owen Mumford: Owen Mumford is a UK-headquartered specialist in pen injectors and autoinjectors (e.g., Autoject, Uniject) for pharma and consumer self-care markets, competing with Ypsomed across both reusable and disposable self-injection platforms.
Emerging players
- Haselmeier: Haselmeier is a German specialist in subcutaneous injection devices including pen injectors and autoinjectors (e.g., Sub-Q, Berpu), competing in pharma drug-delivery with similar platform-customization model to Ypsomed.
Broad incumbents
- Aptar Pharma (Crystal Simple Dreams / Activ-Film): Aptar Pharma is the drug-delivery arm of AptarGroup offering elastomeric components, prefilled syringe components, and connected drug-delivery platforms (e.g., PureFlo, aptar4inject); broader portfolio but overlaps with Ypsomed in pharma elastomeric/combination products.
- Phillips-Medisize (Molex): Phillips-Medisize designs and manufactures drug-delivery devices including autoinjectors, inhalers, and connected platforms for pharma OEMs; competes with Ypsomed in design/development and assembly of self-injection systems.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ypsomed social profiles
Digital presenceYpsomed compliance and trust
Trust signalCompliance5 records
Ypsomed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ypsomed leadership team
Management profileNumber of profiles
Profiles10 records
Ypsomed subsidiaries and ownership
Company hierarchySubsidiaries4 records
Ypsomed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ypsomed M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ypsomed
What does Ypsomed do?
Ypsomed designs, develops, and manufactures self-injection drug delivery systems — pen injectors, prefilled autoinjectors, and wearable patch injectors — together with digital connectivity add-ons, and sells them exclusively in large batches to pharmaceutical and biotechnology companies for use with their drug products. The company leverages a proprietary modular platform architecture to customize delivery devices rapidly and supports customers with regulatory, clinical trial, and manufacturing services across global facilities in Switzerland, Germany, China, and a forthcoming U.S. site.
Is Ypsomed a public or private company?
Ypsomed is a public company. It is classified as public and is currently operating.
When was Ypsomed founded?
Ypsomed was founded in 1984. It employs 1,001 to 5,000 people.
Where is Ypsomed based?
Ypsomed is headquartered in Burgdorf, Switzerland, in the Europe region.
How does Ypsomed make money?
Three revenue lines are on record. Delivery Systems Product Sales are the primary driver. The others are project Business / Development Fees and contract Manufacturing.
Who are Ypsomed's main competitors?
Direct peers on record are BD (Becton, Dickinson and Company) – Pharmaceutical Systems, West Pharmaceutical Services, SHL Medical, Stevanato Group, Gerresheimer, SCHOTT Pharma and Owen Mumford. Haselmeier is listed as an emerging player. Broad incumbents are Aptar Pharma (Crystal Simple Dreams / Activ-Film) and Phillips-Medisize (Molex).
Does Ypsomed have an API?
No public API is recorded for Ypsomed.
What industry is Ypsomed in?
Ypsomed's product category is Self-injection drug delivery devices. Its primary akta.pro industry code is HLAHAIAB, Auto-Injectors (Disposable & Reusable), with a secondary code of HLAHAIAE, Wearable Injectors & On-Body Delivery Systems. Its NAICS code is 339112 and its SIC code is 3841.